相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer
Anna-Larissa N. Niemeijer et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer
Jasper Smit et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)
Emma J. de Ruiter et al.
MODERN PATHOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-D- GLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab
Filippo G. Dall'Olio et al.
EUROPEAN JOURNAL OF CANCER (2021)
Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy
Jannie Borst et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic
David Leung et al.
FRONTIERS IN ONCOLOGY (2021)
Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer 18F-BMS-986192
Thijs S. Stutvoet et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Programmed Cell Death-1/ Ligand-1 PET Imaging A Novel Tool to Optimize Immunotherapy?
Sarah R. Verhoeff et al.
PET CLINICS (2020)
The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients
Paul Hofman
JOURNAL OF THORACIC DISEASE (2019)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E. W. Cohen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy
Madison Canning et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy
Kimiteru Ito et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer
Sandra Heskamp et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas et al.
CANCER CELL (2018)
A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR
L. Siu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Molecular Imaging in Cancer Drug Development
Stijn J. H. Waaijer et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Frederike Bensch et al.
NATURE MEDICINE (2018)
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
A. N. Niemeijer et al.
NATURE COMMUNICATIONS (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
Kevin J. Harrington et al.
LANCET ONCOLOGY (2017)
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Harriet M. Kluger et al.
CLINICAL CANCER RESEARCH (2017)
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
M. Ilie et al.
ANNALS OF ONCOLOGY (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers
Michael Hettich et al.
THERANOSTICS (2016)
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
Yvonne W. S. Jauw et al.
FRONTIERS IN PHARMACOLOGY (2016)
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Ronald Boellaard et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
Jason Madore et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
Multicenter Harmonization of 89Zr PET/CT Performance
Nikolaos E. Makris et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
分享论文
